{"id":16292,"date":"2023-03-07T19:59:58","date_gmt":"2023-03-07T19:59:58","guid":{"rendered":"https:\/\/drugprevent.org.uk\/ppp\/?p=16292"},"modified":"2023-03-28T19:24:35","modified_gmt":"2023-03-28T19:24:35","slug":"acute-illness-associated-with-cannabis-use-by-route-of-exposure-an-observational-study","status":"publish","type":"post","link":"https:\/\/drugprevent.org.uk\/ppp\/2023\/03\/acute-illness-associated-with-cannabis-use-by-route-of-exposure-an-observational-study\/","title":{"rendered":"Acute Illness Associated With Cannabis Use, By Route Of Exposure: An Observational Study"},"content":{"rendered":"
\n

Abstract<\/span><\/h2>\n
\n

Background:\u00a0<\/strong>Little is known about the relative harms of edible and inhalable cannabis products.<\/span><\/p>\n

Objective:\u00a0<\/strong>To describe and compare adult emergency department (ED) visits related to edible and inhaled cannabis exposure.<\/span><\/p>\n

Design:\u00a0<\/strong>Chart review of ED visits between 1 January 2012 and 31 December 2016.<\/span><\/p>\n

Setting:\u00a0<\/strong>A large urban academic hospital in Colorado.<\/span><\/p>\n

Participants:\u00a0<\/strong>Adults with ED visits with a cannabis-related International Classification of Diseases, Ninth or 10th Revision, Clinical Modification (ICD-9-CM or ICD-10-CM), code.<\/span><\/p>\n

Measurements:\u00a0<\/strong>Patient demographic characteristics, route of exposure, dose, symptoms, length of stay, disposition, discharge diagnoses, and attribution of visit to cannabis.<\/span><\/p>\n

Results:\u00a0<\/strong>There were 9973 visits with an ICD-9-CM or ICD-10-CM code for cannabis use. Of these, 2567 (25.7%) visits were at least partially attributable to cannabis, and 238 of those (9.3%) were related to edible cannabis. Visits attributable to inhaled cannabis were more likely to be for cannabinoid hyperemesis syndrome (18.0% vs. 8.4%), and visits attributable to edible cannabis were more likely to be due to acute psychiatric symptoms (18.0% vs. 10.9%), intoxication (48% vs. 28%), and cardiovascular symptoms (8.0% vs. 3.1%). Edible products accounted for 10.7% of cannabis-attributable visits between 2014 and 2016 but represented only 0.32% of total cannabis sales in Colorado (in kilograms of tetrahydrocannabinol) during that period.<\/span><\/p>\n

Limitation:\u00a0<\/strong>Retrospective study design, single academic center, self-reported exposure data, and limited availability of dose data.<\/span><\/p>\n

Conclusion:\u00a0<\/strong>Visits attributable to inhaled cannabis are more frequent than those attributable to edible cannabis, although the latter is associated with more acute psychiatric visits and more ED visits than expected.<\/span><\/p>\n

Primary funding source:\u00a0<\/strong>Colorado Department of Public Health and Environment.<\/span><\/p>\n<\/div>\n<\/div>\n

\n

Figures<\/span><\/h3>\n

\"\"<\/span><\/p>\n

Flow chart of visit selection and review.\u00a0<\/strong><\/span><\/p>\n

ED = emergency department; ICD = International Classification of Diseases.<\/span><\/div>\n<\/div>\n
<\/div>\n
\"\"<\/span><\/div>\n
\n

Figure 2.. Exposure to edible and inhalable cannabis products in cannabis-attributable visits at UCHED from 2012 to 2016.\u00a0<\/strong><\/span><\/p>\n

Error bars indicate 95% CIs. UCHED = UCHealth University of Colorado Hospital Emergency Department.<\/span><\/div>\n<\/div>\n
\n

Source: Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study – PubMed (nih.gov)<\/a> March 2019<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Abstract Background:\u00a0Little is known about the relative harms of edible and inhalable cannabis products. Objective:\u00a0To describe and compare adult emergency department (ED) visits related to edible and inhaled cannabis exposure. Design:\u00a0Chart review of ED visits between 1 January 2012 and 31 December 2016. Setting:\u00a0A large urban academic hospital in Colorado. Participants:\u00a0Adults with ED visits with […]<\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[63,30,64],"tags":[],"class_list":["post-16292","post","type-post","status-publish","format-standard","hentry","category-brain-and-behaviour","category-cannabis-marijuana","category-health"],"_links":{"self":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/16292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/comments?post=16292"}],"version-history":[{"count":0,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/16292\/revisions"}],"wp:attachment":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/media?parent=16292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/categories?post=16292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/tags?post=16292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}